tirzepatide uric acid and change in and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial can tirzepatide cause gout and

This article should not be interpreted as clinical guidance for microdosing practices but should instead serve as a resource for clinicians who may consider microdosing tirzepatide- MDP for patients who would benefit from this alternative dosing strategy Microdosing tirzepatide is not endorsed by the manufacturer or approved by any regulatory agency While microdosing is a reasonable approach to individualizing care the lack of supporting data should give pause to inexperienced users, considering the possible medical and legal implications and liability for dosing errors or adverse events experienced by patients

Scharffetter Kochanek K, Wlaschek M, Brenneisen P, Schauen M, Blaudschun R, et al

Also, many patients discontinued treatment before the end of the study period

Frequently Asked Questions About AOD-9604 Safety How many people have been studied in AOD-9604 clinical trials

You can read all about the pure form here

in severe overdoses it can cause coma or death